̽»¨¾«Ñ¡

Olivia Ojala

Olivia Ojala

Postdoktorala Studier
E-postadress: olivia.ojala@ki.se
µþ±ð²õö°ì²õ²¹»å°ù±ð²õ²õ: Norra Stationsgatan 69, plan 7, 11364 Stockholm
Postadress: K8 Klinisk neurovetenskap, K8 CPF Bjureberg, 171 77 Stockholm

Om mig

  • Jag är legitimerad psykolog och postdoktor pÃ¥ Centrum för Psykiatriforskning,  

    Mina forskningsintressen och arbete berör främst ungda med icke-suicidalt självskadebeteende. 

    Mitt fokus är att förstÃ¥ uppkomsten och utveckla samt utvärdera behandlingar för ungdomar med självskadebeteende. 

Utvalda publikationer

  • Doctoral thesis: 2023
    Ojala O
  • Article: JAMA NETWORK OPEN. 2023;6(7):e2322069
    Bjureberg J; Ojala O; Hesser H; Habel H; Sahlin H; Gratz KL; Tull MT; Claesdotter Knutsson E; Hedman-Lagerlof E; Ljotsson B; Hellner C
  • Article: BMC PSYCHIATRY. 2022;22(1):679
    Ojala O; Kuja-Halkola R; Bjureberg J; Ohlis A; Cederlof M; Selinus EN; Lichtenstein P; Larsson H; Lundstrom S; Hellner C
  • Article: JMIR FORMATIVE RESEARCH. 2021;5(7):e17910
    Simonsson O; Engberg H; Bjureberg J; Ljotsson B; Stensils J; Sahlin H; Hellner C

Artiklar

  • Article: JMIR MENTAL HEALTH. 2025;12:e74303
    Bjureberg J; Ojala O; Rasmusson B; Malmgren J; Hellner C; Sampaio F; Flygare O
  • Journal article: COGNITIVE BEHAVIOUR THERAPY. 2025;:1-16
    Larsson J; Ojala O; Bjureberg J; Sederstroem P; Hvass O; Bjoerk P; Lidskog S; Hesser H
  • Article: PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE. 2025;98(2):322-341
    Christensen SH; Heinrichsen M; Mohl B; Rubaek L; Byrialsen KK; Ojala O; Hellner C; Pagsberg AK; Bjureberg J; Morthorst B
  • Article: COGNITIVE BEHAVIOUR THERAPY. 2025;54(2):231-245
    Flygare O; Ojala O; Ponten M; Klintwall L; Karemyr M; Sjoblom K; Wallert J; Hellner C; Nilbrink J; Bellander M; Bjureberg J
  • Article: BMC PSYCHIATRY. 2025;25(1):36
    Forsstrom D; Badinlou F; Johansson M; Ojala O; Alaoui SE; Mansson KNT; Rozental A; Lundin J; Jangard S; Shahnavaz S; Sorman K; Jayaram-Lindstrom N; Lundgren T; Jansson-Frojmark M; Hedman-Lagerlof M
  • Article: BMC PSYCHIATRY. 2024;24(1):904
    Ponten M; Flygare O; Bellander M; Karemyr M; Nilbrink J; Hellner C; Ojala O; Bjureberg J
  • Article: PLOS ONE. 2024;19(11):e0313961
    Ojala O; Garke MA; El Alaoui S; Forsstrom D; Hedman-Lagerlof M; Jangard S; Lundin J; Rozental A; Shahnavaz S; Sorman K; Lundgren T; Hellner C; Jayaram-Lindstrom N; Mansson KNT
  • Article: JCPP ADVANCES. 2024;4(3):e12243
    Ojala O; Hesser H; Gratz KL; Tull MT; Hedman-Lagerlof E; Sahlin H; Ljotsson B; Hellner C; Bjureberg J
  • Article: PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE. 2023;96(2):410-425
    Ohlis A; Bjureberg J; Ojala O; Kerj E; Hallek C; Fruzzetti AE; Hellner C
  • Article: JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY. 2023;91(5):254-266
    Bjureberg J; Ojala O; Berg A; Edvardsson E; Kolbeinsson O; Molander O; Morin E; Nordgren L; Palme K; Sarnholm J; Wedin L; Ruck C; Gross JJJ; Hesser H
  • Article: CURRENT PSYCHOLOGY. 2023;42(13):10987-10998
    Nilsson A; Simonsson O; Hellner C
  • Article: FRONTIERS IN PSYCHOLOGY. 2022;13:1045709
    Forsstrom D; Lindner P; Mansson KNT; Ojala O; Hedman-Lagerlof M; El Alaoui S; Rozental A; Lundin J; Jangard S; Shahnavaz S; Sorman K; Lundgren T; Jayaram-Lindstrom N
  • Article: JCPP ADVANCES. 2022;2(4):e12115
    Morthorst B; Olsen MH; Jakobsen JC; Lindschou J; Gluud C; Heinrichsen M; Mohl B; Rubaek L; Ojala O; Hellner C; Bjureberg J; Pagsberg AK
  • Article: FRONTIERS IN PSYCHIATRY. 2022;13:933858
    Rozental A; Soerman K; Ojala O; Jangard S; El Alaoui S; Mansson KNT; Shahnavaz S; Lundin J; Forsstroem D; Hedman-Lagerloef M; Lundgren T; Jayaram-Lindstroem N
  • Article: TRIALS. 2021;22(1):456
    Olsen MH; Morthorst B; Pagsberg AK; Heinrichsen M; Mohl B; Rubaek L; Bjureberg J; Simonsson O; Lindschou J; Gluud C; Jakobsen JC

Alla övriga publikationer

  • Preprint: PSYARXIV. 2025
    Jangard S; Vieira J; Garke MÅ; Ojala O; Månsson K; Sörman K; Alaoui SE; Hedman-Lagerlöf M; Rozental A; Forsström D; Lundin J; Shahnavaz S; Lundgren T; Olsson A; Jayaram-Lindström N
  • Preprint: PSYARXIV. 2024
    Bjureberg J; Ojala O; Rasmusson B; Malmgren J; Hellner C; Flygare O
  • Preprint: PSYARXIV. 2024
    Ponten M; Flygare O; Bellander M; Karemyr M; Nilbrink J; Hellner C; Ojala O; Bjureberg J
  • Corrigendum: BMC PSYCHIATRY. 2023;23(1):864
    Ojala O; Kuja-Halkola R; Bjureberg J; Ohlis A; Cederlof M; Selinus EN; Lichtenstein P; Larsson H; Lundstrom S; Hellner C
  • Preprint: PSYARXIV. 2023
    Flygare O; Ojala O; Ponten M; Klintwall L; Karemyr M; Sjöblom K; Wallert J; Hellner C; Nilbrink J; Bellander M; Bjureberg J

Forskningsbidrag

  • Swedish Research Council for Health Working Life and Welfare
    1 January 2025 - 31 December 2027
    Research problem and specific questionsSelf-injury is a growing and urgent health crisis among youth and the strongest risk factor for suicide attempts. Scalable and evidence-based treatments are needed but lacking. We have recently shown that a brief digital treatment, IERITA (Internet-delivered Emotion Regulation Individual Therapy for Adolescents), can be efficacious and cost-effective compared to treatment as usual only. However, not all patients respond sufficiently to the standard treatment procedure, and established efficacy does not guarantee successful uptake in regular care. This project aims to implement and evaluate IERITA in real-world settings and optimize treatment outcomes. The key question concerns the effectiveness and cost-effectiveness of changing to an adapted version of IERITA compared to continuing standard IERITA for adolescents at risk of continued self-injury after treatment (non-remission). Data and methodFirst, a classification tool to predict non-remission will be developed and subsequently used in the second step: a randomized controlled trial (N=341) comparing adaptable to standard IERITA. Adolescents allocated to adaptable IERITA and classified as likely non-remission in treatment week four will change to adapted IERITA (e.g., personalized dose and treatment delivery) for the remaining eight weeks. Several clinically relevant outcomes will be measured using blinded assessment, including remission (primary outcome), self-injury frequency, suicidality, and functional impairment. Participants will be followed up one- three- and twelve months post-treatment and in national registers. Societal relevance and utilisationSelf-injury is rapidly increasing, posing severe risks for youths. The queue to healthcare services is long, and current treatments are costly and not widely or equally accessible. If this project is successful, more youths across the country could receive effective early intervention for self-injury, with the hope of reduced waiting times, equal care, and suicide preventive effects. Plan for project realisationThe project will be conducted within child and adolescent mental health services. In previous studies, we have successfully collaborated with several regions. Patient organizations and health professionals will contribute to increasing relevance and feasibility. The budget includes salaries (applicant, project coordinator, patient organization, blinded assessors) and operating costs.
  • Swedish Research Council for Health Working Life and Welfare
    1 January 2025 - 31 December 2025
    Research idea and purposeSelf-injury is a growing and urgent health crisis among youth and the strongest risk factor for suicide attempts. Scalable and evidence-based treatments are needed but lacking. We have recently shown that a brief digital treatment, IERITA (Internet-delivered Emotion Regulation Individual Therapy for Adolescents), can be efficacious compared to treatment as usual only. However, not all patients respond sufficiently to the standard treatment procedure, and established efficacy does not guarantee successful uptake in regular care. This project aims to implement and evaluate IERITA in real-world settings and optimize treatment outcomes. A planning grant creates opportunities to test the project´s feasibility, an essential part of preparation for a large-scale study.Work plan, methods and project realisationFirst, a classification tool to predict continued self-injury after treatment (non-remission) will be developed and subsequently used in a randomized controlled pilot trial (N=30) comparing adaptable to standard IERITA. Adolescents allocated to adaptable IERITA and classified as likely non-remission in treatment week four will change to adapted IERITA (e.g., personalized dose and treatment delivery) for the remaining eight weeks. Feasibility will be evaluated through the number of completed treatment parts, degree of participation in data collection, satisfaction, adherence, and therapist time. Clinically relevant outcomes will also be measured, which include remission (primary clinical outcome), frequency of self-injurious behaviour, suicidality and level of functioning. Participants will be followed up one- and three months post-treatment. The project will be conducted within regular health care services in several regions which we have collaborated with previously. Patient organizations and health professionals will contribute to increasing relevance and feasibility. The budget includes salaries for the project manager and patient organization, and a smaller part for operating costs.Societal relevance and utilisationSelf-injury is rapidly increasing, posing severe risks for youths. The queue to healthcare services is long, and current treatments are costly and not widely or equally accessible. If this project is successful, more youths across the country could receive effective early intervention for self-injury, with the hope of reduced waiting times, equal care, and suicide preventive effects.
  • Swedish Research Council
    1 January 2025 - 31 December 2028
    Self-injury is a growing health crisis among youth, and the strongest risk factor for suicide attempts. Scalable treatments are needed but lacking. We have recently shown that a brief digital treatment, IERITA (Internet-delivered Emotion Regulation Individual Therapy for Adolescents), can be efficacious and cost-effective. However, not all patients respond sufficiently to the standard treatment procedure. Now we aim to implement and evaluate IERITA within regular health services and optimize treatment outcomes. First, we will develop and validate a classification tool to predict non-remission (continued self-injury after treatment). This tool will subsequently be used in the second step: a randomized controlled trial (N=341) between 2025 to 2028, which compares adaptable to standard IERITA. Adolescents allocated to adaptable IERITA and classified as likely non-remission in treatment week four will recieve adapted IERITA (e.g., personalized dose and treatment delivery) for the remaining eight weeks. We will (1) follow participants one- three- and twelve-month post-treatment
    (2) use self-reports and blinded assessments
    (3) study distal effects in national registers
    (4) investigate several clinically relevant outcomes
    and (5) conduct cost-effectiveness analyses. If successful, more patients could receive evidence-based treatment for self-injury, and treatment outcomes could be improved. In extension, queues to care may be reduced, and suicide attempts and suicides prevented.

´¡²Ô²õ³Ùä±ô±ô²Ô¾±²Ô²µ²¹°ù

  • Postdoktorala Studier, Klinisk neurovetenskap, ̽»¨¾«Ñ¡, 2023-2026

Examina och utbildning

  • Medicine Doktorsexamen, Institutionen för klinisk neurovetenskap, ̽»¨¾«Ñ¡, 2023
  • Psykologexamen, ̽»¨¾«Ñ¡, 2017

Nyheter från KI

Kalenderhändelser från KI